Harvard Bioscience
HBIO
89 hedge funds and large institutions have $138M invested in Harvard Bioscience in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 40 reducing their positions, and 10 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.24% less ownership
Funds ownership: 7.73% → 7.49% (-0.24%)
4% less funds holding
Funds holding: 93 → 89 (-4)
22% less capital invested
Capital invested by funds: $176M → $138M (-$38.6M)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
33% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 40
37% less call options, than puts
Call options by funds: $19K | Put options by funds: $30K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AE
AMH Equity
Great Neck,
New York
|
+$725K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$232K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$223K |
| 4 |
New York State Common Retirement Fund
Albany,
New York
|
+$161K |
| 5 |
HIM
Hillsdale Investment Management
Toronto,
Ontario, Canada
|
+$119K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAIM
Punch & Associates Investment Management
Edina,
Minnesota
|
-$655K |
| 2 |
2C
272 Capital
Dallas,
Texas
|
-$469K |
| 3 |
RA
Royce & Associates
New York
|
-$459K |
| 4 |
CIC
Cornercap Investment Counsel
Atlanta,
Georgia
|
-$418K |
| 5 |
BlackRock
New York
|
-$360K |
HBIO Hedge Fund Activity: Q1 2024 in Review
89 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Harvard Bioscience (HBIO) for Q1 2024, worth a combined $138M — down 22% from $176M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of HBIO and 7 opened new positions — a net loss of 3 holders — while 40 trimmed existing stakes and 27 added.
The largest buyer was AMH Equity, adding an estimated $725K. The largest seller was Punch & Associates Investment Management, cutting an estimated $655K.
- 89 institutional investors held Harvard Bioscience (HBIO) as of Q1 2024, down from 93 in Q4 2023.
- Funds reported $138M of Harvard Bioscience stock for Q1 2024, down 22% quarter-over-quarter.
- 7 funds opened new Harvard Bioscience positions in Q1 2024 and 10 closed out, a net change of -3 holders.
- The largest Harvard Bioscience buyer in Q1 2024 was AMH Equity, an estimated $725K added.
- The largest Harvard Bioscience seller in Q1 2024 was Punch & Associates Investment Management, an estimated $655K sold.
Based on aggregated 13F filings for Q1 2024.